EFFICACY AND SAFETY OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 INHIBITORS TREATMENT ON CHOLESTEROL LEVELS: A COMPREHENSIVE META-ANALYSIS OF ALL RANDOMIZED CLINICAL TRIALS

Armaghan Y. Soomro,Mark Ediger,Bhavi Pandya,Muhammad Raza,Zaka Khan,Mustafain Meghani,Sarah Tareen,Thomas Vazzana,James Lafferty

EFFICACY AND SAFETY OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 INHIBITORS TREATMENT ON CHOLESTEROL LEVELS: A COMPREHENSIVE META-ANALYSIS OF ALL RANDOMIZED CLINICAL TRIALS

2016

Armaghan Y. Soomro
Mark Ediger
Bhavi Pandya
Muhammad Raza
Zaka Khan
Mustafain Meghani
Sarah Tareen
Thomas Vazzana
James Lafferty

Recent clinical trials have demonstrated concomitant lipid lowering treatments (LLT) with Proprotein Convertase Subtilisin/Kexin type 9 inhibitors (PCSK9I) effective in reducing blood LDL levels in hypercholesterolemia. We conducted a meta-analysis to assess the efficacy and safety of PCSK9I. A

Keywords:

Subtilisin
Kexin
Randomized controlled trial
Proprotein convertase
Cholesterol
Medicine
Cardiology
Internal medicine
Clinical trial
Concomitant
Pharmacology
Diabetes mellitus

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations